secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0000950170-23-011416
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atara CFO Utpal Koppikar resigns effective March 31; enters six-month consulting agreement
--------------------------------------------------------------------------------

- Utpal Koppikar resigned as CFO effective March 31, 2023, and entered a six-month consulting agreement.
- Consulting fee: $2,800/month for up to a specified number of hours, plus $175/hour for excess hours.
- Outstanding equity awards will continue to vest during the consulting term.
- No successor named in the filing; search for new CFO is presumably ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023011416/0000950170-23-011416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023011416/atra-20230331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-011416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer